MX2019013373A - Terapias de combinación para tratar cáncer. - Google Patents

Terapias de combinación para tratar cáncer.

Info

Publication number
MX2019013373A
MX2019013373A MX2019013373A MX2019013373A MX2019013373A MX 2019013373 A MX2019013373 A MX 2019013373A MX 2019013373 A MX2019013373 A MX 2019013373A MX 2019013373 A MX2019013373 A MX 2019013373A MX 2019013373 A MX2019013373 A MX 2019013373A
Authority
MX
Mexico
Prior art keywords
treating cancer
combination therapies
signaling
agent
inhibits
Prior art date
Application number
MX2019013373A
Other languages
English (en)
Inventor
Andrew R Ferguson
Bruce Dezube
Peng Sun
Dmitri Bobilev
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MX2019013373A publication Critical patent/MX2019013373A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K1/00—Housing animals; Equipment therefor
    • A01K1/01—Removal of dung or urine, e.g. from stables
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/20—Analysis of motion
    • G06T7/215—Motion-based segmentation
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R13/00—Details of coupling devices of the kinds covered by groups H01R12/70 or H01R24/00 - H01R33/00
    • H01R13/46—Bases; Cases
    • H01R13/516—Means for holding or embracing insulating body, e.g. casing, hoods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos de tratamiento para cánceres recurrentes a través de terapia de combinación con un agente que inhibe la señalización de la proteína de muerte programada 1 (PD-1) y un agente que inhibe la señalización de poli [ADP-ribosa] polimerasa (PARP).
MX2019013373A 2017-05-09 2018-05-09 Terapias de combinación para tratar cáncer. MX2019013373A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762503879P 2017-05-09 2017-05-09
US201762508359P 2017-05-18 2017-05-18
US201762556255P 2017-09-08 2017-09-08
US201862634789P 2018-02-23 2018-02-23
US201862646332P 2018-03-21 2018-03-21
US201862648327P 2018-03-26 2018-03-26
PCT/US2018/031876 WO2018208968A1 (en) 2017-05-09 2018-05-09 Combination therapies for treating cancer

Publications (1)

Publication Number Publication Date
MX2019013373A true MX2019013373A (es) 2020-08-03

Family

ID=64105496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013373A MX2019013373A (es) 2017-05-09 2018-05-09 Terapias de combinación para tratar cáncer.

Country Status (12)

Country Link
US (1) US20200289493A1 (es)
EP (1) EP3621592A4 (es)
JP (2) JP2020519621A (es)
KR (1) KR20200018436A (es)
CN (1) CN110831580A (es)
AU (3) AU2018264992A1 (es)
BR (1) BR112019023591A2 (es)
CA (1) CA3063201A1 (es)
MA (1) MA48637A (es)
MX (1) MX2019013373A (es)
TW (1) TW201906632A (es)
WO (1) WO2018208968A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
EP3615513B1 (en) 2017-04-24 2022-07-20 Tesaro, Inc. Methods of manufacturing of niraparib
BR112019024135A2 (pt) 2017-05-18 2020-06-02 Tesaro, Inc. Terapias de combinação para o tratamento de câncer
SG11202002113TA (en) 2017-09-26 2020-04-29 Tesaro Inc Niraparib formulations
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
SG11202002499TA (en) 2017-10-06 2020-04-29 Tesaro Inc Combination therapies and uses thereof
TW201938165A (zh) * 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
JP2024509018A (ja) * 2021-03-12 2024-02-29 中山康方生物医▲藥▼有限公司 抗ｐｄ－１－抗ｖｅｇｆａ二重特異性抗体を含有する組合せ医薬及びその使用
WO2022271547A1 (en) 2021-06-21 2022-12-29 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
WO2023159066A1 (en) 2022-02-15 2023-08-24 Tesaro, Inc. Use of niraparib for the treatment of brain cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707302B2 (en) * 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP2217227B1 (en) * 2007-11-12 2013-08-21 BiPar Sciences, Inc. Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
WO2011153383A1 (en) * 2010-06-04 2011-12-08 Bipar Science, Inc. Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
EP3080292B1 (en) * 2013-12-09 2022-02-02 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2015108986A1 (en) * 2014-01-16 2015-07-23 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
EP3498734B1 (en) * 2014-02-04 2021-09-01 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
JP6588461B2 (ja) * 2014-03-31 2019-10-09 ジェネンテック， インコーポレイテッド 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
US20150344968A1 (en) * 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
KR20170138555A (ko) * 2015-04-28 2017-12-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
KR20180025888A (ko) * 2015-06-08 2018-03-09 제넨테크, 인크. 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
PT3313443T (pt) * 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
SI3337467T1 (sl) * 2015-08-20 2021-03-31 Ipsen Biopharm Ltd. Ash Road Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka
KR20230042136A (ko) * 2016-06-29 2023-03-27 테사로, 인코포레이티드 난소암의 치료 방법
MX2019012793A (es) * 2017-04-27 2020-02-13 Tesaro Inc Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.

Also Published As

Publication number Publication date
AU2021218080B2 (en) 2023-12-14
WO2018208968A1 (en) 2018-11-15
JP2023093603A (ja) 2023-07-04
TW201906632A (zh) 2019-02-16
US20200289493A1 (en) 2020-09-17
MA48637A (fr) 2021-03-17
EP3621592A1 (en) 2020-03-18
JP2020519621A (ja) 2020-07-02
KR20200018436A (ko) 2020-02-19
CN110831580A (zh) 2020-02-21
AU2023274126A1 (en) 2024-02-01
AU2018264992A1 (en) 2019-12-05
BR112019023591A2 (pt) 2020-05-26
EP3621592A4 (en) 2021-03-17
AU2021218080A1 (en) 2021-09-09
CA3063201A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
MX2019013373A (es) Terapias de combinación para tratar cáncer.
MX2019013755A (es) Terapias de combinación para el tratamiento del cáncer.
PH12017501857A1 (en) Pd-l1 antagonist combination treatments
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2017015308A (es) Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer.
MA39906A (fr) Polythérapies pour le traitement du cancer
PH12016501550B1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
MX2016010082A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
MX2015011428A (es) Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
MX2019011657A (es) Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer.
PH12019501373A1 (en) Methods of treating cochlears synaptopathy
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2020006297A (es) Variantes de cd19.
MX2018015172A (es) Metodos para tratar cancer pancreatico.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
EP3615056A4 (en) METHODS AND COMPOSITIONS FOR THE SCREENING AND TREATMENT OF CANCER
MX2017015311A (es) Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.